Senestech (SNES) Registration Filing summary

Company overview and business model

• Develops and commercializes fertility control products for managing rat and mouse populations, including ContraPest, Evolve Rat, and Evolve Mouse.

• ContraPest is a liquid bait targeting reproductive systems of rats, registered in all 50 states and two U.S. territories.

• Evolve Rat, launched in January 2024, is a soft bait using cottonseed oil, exempt from federal registration and authorized in 48 states.

• Evolve Mouse, launched in May 2024, is authorized in 35 states and uses a similar formulation to Evolve Rat.

• Continuously enhances products and pursues regulatory approvals to expand market reach.

Financial performance and metrics

• Identified as a smaller reporting company with public float below $700 million and annual revenue under $100 million.

• As of March 7, 2025, aggregate market value of outstanding common equity held by non-affiliates was $5,345,016, with 1,775,930 shares outstanding.

• Has incurred operating losses since inception and expects continued significant expenses and losses.

• Financial statements for 2024 and 2023 include a going concern warning due to net loss from operations and net capital deficiency.

Use of proceeds and capital allocation

• Net proceeds from offerings will be used for working capital and general corporate purposes, including R&D, capital expenditures, and administrative expenses.

• Management has broad discretion over use of proceeds; funds may be invested in short-term, investment grade, interest-bearing securities pending use.